Your browser is no longer supported. Please, upgrade your browser.
Settings
AQST [NASD]
Aquestive Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own4.40% Shs Outstand33.62M Perf Week-3.71%
Market Cap141.91M Forward P/E- EPS next Y-1.72 Insider Trans-5.08% Shs Float29.64M Perf Month-21.95%
Income-48.10M PEG- EPS next Q-0.26 Inst Own57.30% Short Float4.21% Perf Quarter-34.38%
Sales55.10M P/S2.58 EPS this Y11.80% Inst Trans-3.66% Short Ratio1.29 Perf Half Y-43.53%
Book/sh-1.09 P/B- EPS next Y-28.40% ROA-74.80% Target Price- Perf Year6.52%
Cash/sh0.53 P/C8.30 EPS next 5Y- ROE226.50% 52W Range1.41 - 9.47 Perf YTD-17.57%
Dividend- P/FCF- EPS past 5Y-36.50% ROI-106.20% 52W High-53.41% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y90.00% Gross Margin69.20% 52W Low212.77% ATR0.53
Employees232 Current Ratio1.70 Sales Q/Q-33.10% Oper. Margin-67.30% RSI (14)37.23 Volatility15.46% 9.98%
OptionableYes Debt/Eq- EPS Q/Q33.10% Profit Margin-87.20% Rel Volume1.19 Prev Close4.22
ShortableYes LT Debt/Eq- EarningsMar 09 AMC Payout- Avg Volume969.34K Price4.41
Recom1.80 SMA20-21.45% SMA50-21.48% SMA200-26.12% Volume1,153,074 Change4.50%
Apr-22-19Initiated H.C. Wainwright Buy
Jan-03-19Initiated Lake Street Buy $14
Aug-20-18Initiated RBC Capital Mkts Outperform $23
Aug-20-18Initiated JMP Securities Mkt Outperform $29
Mar-07-21 01:36AM  
Mar-06-21 11:19AM  
Mar-05-21 12:30PM  
12:07PM  
11:30AM  
10:00AM  
07:00AM  
Mar-04-21 01:10PM  
12:31PM  
11:45AM  
11:00AM  
11:00AM  
09:42AM  
09:09AM  
09:00AM  
Mar-03-21 08:35PM  
06:30PM  
05:27PM  
01:47PM  
11:12AM  
10:33AM  
10:16AM  
10:00AM  
Mar-02-21 04:02PM  
12:30PM  
11:15AM  
Mar-01-21 11:27PM  
Feb-25-21 11:07AM  
07:30AM  
Feb-17-21 07:30AM  
Feb-09-21 07:30AM  
Jan-28-21 10:12AM  
07:30AM  
Jan-21-21 08:30AM  
Jan-07-21 07:30AM  
Jan-06-21 12:22AM  
Jan-04-21 07:30AM  
Dec-16-20 08:00AM  
Dec-07-20 10:21PM  
Nov-25-20 09:15AM  
Nov-23-20 07:00AM  
Nov-19-20 08:17AM  
Nov-18-20 04:01PM  
Nov-07-20 07:39AM  
Nov-05-20 10:02PM  
06:15AM  
Nov-04-20 07:55PM  
04:30PM  
08:21AM  
Nov-03-20 07:00AM  
Oct-28-20 12:33PM  
Oct-19-20 07:21AM  
Oct-14-20 07:30AM  
Sep-30-20 11:00AM  
Sep-29-20 06:06PM  
Sep-28-20 04:25AM  
Sep-25-20 05:38PM  
08:51AM  
Sep-17-20 10:11AM  
Aug-20-20 08:11AM  
07:30AM  
Aug-18-20 11:06AM  
Aug-10-20 07:30AM  
Aug-05-20 06:31PM  
Aug-04-20 07:35PM  
04:01PM  
08:18AM  
Jul-28-20 04:15PM  
12:33PM  
Jul-15-20 07:57AM  
Jul-06-20 09:49AM  
Jun-29-20 07:00AM  
Jun-25-20 11:22AM  
Jun-16-20 08:00AM  
Jun-04-20 05:05PM  
May-28-20 09:42AM  
May-27-20 09:22AM  
May-22-20 07:10AM  
May-21-20 05:27PM  
May-20-20 11:30AM  
May-14-20 08:25AM  
May-12-20 12:00PM  
May-08-20 08:15AM  
May-07-20 02:00PM  
May-06-20 06:00PM  
May-05-20 04:05PM  
Apr-28-20 12:34PM  
Apr-26-20 07:51AM  
Apr-21-20 09:15AM  
Apr-15-20 08:50AM  
Apr-14-20 09:13AM  
Mar-17-20 07:00AM  
Mar-14-20 08:15AM  
Mar-13-20 10:23AM  
Mar-11-20 06:25PM  
04:30PM  
Mar-05-20 12:30PM  
Mar-03-20 03:00PM  
Feb-20-20 07:00AM  
Feb-10-20 07:00AM  
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 10Sale6.7523,460158,355837,000Feb 10 08:17 PM
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 09Sale6.7511,54077,895860,460Feb 10 08:17 PM
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 08Sale6.5040,792265,148872,000Feb 09 04:00 PM
Maxwell John T.SVP-Chief Financial OfficerAug 18Sale8.003,00024,000150,614Aug 19 08:55 AM
Kendall Keith JCEO and PresidentJun 30Option Exercise0.003330639,297Jul 02 04:00 PM
Schobel Alexander MarkChief Innovation/Tech OfficerJun 30Option Exercise0.003330912,886Jul 02 04:00 PM
Kendall Keith JCEO and PresidentJun 04Sale5.1150,000255,310638,964Jun 05 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMay 31Option Exercise0.0014,5720916,685Jun 02 05:14 PM
Kendall Keith JCEO and PresidentMay 31Option Exercise0.0014,5720695,456Jun 02 05:13 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMay 08Sale5.0040,000200,000902,113May 11 04:15 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 29Sale4.5040,000180,0001,022,113May 01 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 27Sale4.0040,000160,000942,113May 04 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 14Sale3.7040,000148,000982,113May 04 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMar 31Option Exercise0.0032901,062,210Apr 02 04:16 PM
Kendall Keith JCEO and PresidentMar 31Option Exercise0.003290680,983Apr 02 04:16 PM
BRAENDER LORI JSVP, General CounselMar 16Buy1.5414,00021,62425,000Mar 18 04:45 PM
Boyd Peter E.SVP-Bus. Process & Info. Tech.Mar 16Buy1.502,0003,00052,239Mar 18 04:45 PM